The historical rank and industry rank for Walpar Nutritions's ROE % or its related term are showing as below:
NSE:WALPAR's ROE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.02 * Ranked among companies with meaningful ROE % only.
Walpar Nutritions (NSE:WALPAR) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2024) net income data. The Revenue data used here is two times the semi-annual (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Walpar Nutritions ROE % Related Terms
Walpar Nutritions ROE % Historical Data
* Premium members only.
The historical data trend for Walpar Nutritions's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Walpar Nutritions's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Walpar Nutritions ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Walpar Nutritions's ROE % distribution charts can be found below:
* The bar in red indicates where Walpar Nutritions's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2024) net income data.
ROE % is displayed in the 30-year financial page.
Walpar Nutritions (NSE:WALPAR) has a ROE % of 17.42% as of Mar. 2024. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Walpar Nutritions and its competitors.
Is Walpar Nutritions' ROE % too high?
Walpar Nutritions' current ROE % is 17.42%. The Drug Manufacturers industry median ROE % is 6.02. Walpar Nutritions' value of 17.42% is 189.4% above this industry median. Overall, Walpar Nutritions has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Walpar Nutritions' ROE % compare to ZTS and VTRS?
Walpar Nutritions' ROE % of 17.42% can be compared against companies in the Drug Manufacturers industry. The industry median ROE % is 6.02. Walpar Nutritions' value of 17.42% is 189.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.02, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Walpar Nutritions's current ROE % of 17.42% is 189.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Walpar Nutritions and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Walpar Nutritions's current ROE % is 17.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Walpar Nutritions stock overvalued right now?
Walpar Nutritions (NSE:WALPAR) has a current ROE % of 17.42%. The current ROE % is 17.42% and 189.4% above the Drug Manufacturers industry median of 6.02. Walpar Nutritions' overall GF Score™ is 54/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Walpar Nutritions (NSE:WALPAR), the current ROE % is 17.42% as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Walpar Nutritions Ltd is India-based company, which is engaged in manufacturing and trading of pharmaceutical, nutraceutical, herbal and ayurvedic commodities. It also manufactures various private label/third party brands for different companies across the country and overseas, as well as for their own brand sales. It is a manufacturer of various types of nutraceutical formulation, pharmaceutical ingredients, and pharmaceutical formulations. It specializes in contract manufacturing, raw materials trading, and direct selling. Its portfolio consists of tablets, capsules, powder/sachets, and oral liquids.
54GF Score
Get the complete analysis for NSE:WALPAR
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WALPAR has been successfully added to your 
